Vyriad teams with Mayo Clinic on antibody detection
Vyriad’s Immuno-Cov neutralizing antibody test formed the basis of a test that Mayo Clinic launched in June to measure the level of neutralizing antibodies against SARS-CoV-2, the virus causing COVID-19. The test provides semi-quantitative detection of total neutralizing antibodies in human serum.
After infection, most will develop an immune response to COVID-19, including the production of neutralizing antibodies against the SARS-CoV-2 spike glycoprotein. Rochester, Minn.-based Vyriad worked with sister company Imanis Life Sciences and Regeneron Pharmaceuticals (NSDQ:REGN) on developing the test.